menu
    • menu
    [{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Afatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Afatinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ubenimex","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ubenimex","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ubenimex","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Afatinib

    Menu

    Afatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Delta-Fly Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Delta-Fly Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delta-Fly Pharma Inc. Progress Update of the Phase III Clinical Trial of DFP-14323

                            Details : DFP-14323 (Ubenimex) is a small molecule CD13 inhibitor, currently being investigated in combination with Afatinib for patients with EGFR-mutated Non-Small-Cell Lung Cancer.

                            Brand Name : DFP-14323

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 26, 2024

                            Lead Product(s) : ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Delta-Fly Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Delta-Fly Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delta-Fly Pharma Begins Phase III Trial of DFP-14323

                            Details : DFP-14323 (Ubenimex) is a small molecule CD13 inhibitor, currently being investigated in combination with Afatinib for patients with EGFR-mutated Non-Small-Cell Lung Cancer.

                            Brand Name : DFP-14323

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 03, 2024

                            Lead Product(s) : ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Delta-Fly Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Delta-Fly Pharma

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delta-Fly Pharma Initiates Phase III Trial Of DFP-14323

                            Details : Delta-Fly (ubenimex) is an aminopeptidase N inhibitor under Phase 3 trials in combination with afatinib for treating stage III/IV non-small cell lung cancer patients with EGFR mutations.

                            Brand Name : DFP-14323

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2024

                            Lead Product(s) : ubenimex,Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ECOG-ACRIN Cancer Research Group

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ECOG-ACRIN Cancer Research Group

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genomic Study of 6000 NCI-MATCH Cancer Patients Leads to New Clinical Trial Benchmarks

                            Details : The NCI-MATCH, a precision medicine study launched by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute, has found that many patients’ tumors bear genetic abnormalities that can be targeted with existing drugs—approved or experim...

                            Brand Name : Gilotrif

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 14, 2020

                            Lead Product(s) : Afatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Afatinib,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Additional Analysis of Real-World Data Confirms Sequential Gilotrif® Followed By Osimertinib Imporved Surviva...

                            Details : Sequential Gilotrif® (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years among U.S. patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance...

                            Brand Name : Gilotrif

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2020

                            Lead Product(s) : Afatinib,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth